337 related articles for article (PubMed ID: 25117800)
1. Cure of HIV infection: is the long wait over?
Shearer WT
J Allergy Clin Immunol; 2014 Jul; 134(1):20-2. PubMed ID: 25117800
[No Abstract] [Full Text] [Related]
2. Progress in HIV-1 vaccine development.
Haynes BF; Moody MA; Alam M; Bonsignori M; Verkoczy L; Ferrari G; Gao F; Tomaras GD; Liao HX; Kelsoe G
J Allergy Clin Immunol; 2014 Jul; 134(1):3-10; quiz 11. PubMed ID: 25117798
[TBL] [Abstract][Full Text] [Related]
3. Lessons learned from HIV-1 vaccine trials: new priorities and directions.
McMichael AJ; Haynes BF
Nat Immunol; 2012 Apr; 13(5):423-7. PubMed ID: 22513323
[TBL] [Abstract][Full Text] [Related]
4. PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey.
Fauci AS; Marston HD
Science; 2015 Jul; 349(6246):386-7. PubMed ID: 26206922
[No Abstract] [Full Text] [Related]
5. HIV-1 T-cell vaccines: evaluating the next step.
Pantaleo G
Lancet Infect Dis; 2008 Feb; 8(2):82-3. PubMed ID: 18060842
[No Abstract] [Full Text] [Related]
6. Elucidating the elite: mechanisms of control in HIV-1 infection.
O'Connell KA; Bailey JR; Blankson JN
Trends Pharmacol Sci; 2009 Dec; 30(12):631-7. PubMed ID: 19837464
[TBL] [Abstract][Full Text] [Related]
7. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
8. HIV neutralizing antibodies reignite interest in vaccine.
Waltz E
Nat Biotechnol; 2012 Mar; 30(3):204-5. PubMed ID: 22398603
[No Abstract] [Full Text] [Related]
9. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
Gudmundsdotter L; Wahren B; Haller BK; Boberg A; Edbäck U; Bernasconi D; Buttò S; Gaines H; Imami N; Gotch F; Lori F; Lisziewicz J; Sandström E; Hejdeman B
Vaccine; 2011 Jul; 29(33):5558-66. PubMed ID: 21300092
[TBL] [Abstract][Full Text] [Related]
10. The emerging race to cure HIV infections.
Cohen J
Science; 2011 May; 332(6031):784-5, 787-9. PubMed ID: 21566173
[No Abstract] [Full Text] [Related]
11. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
12. Eradication of HIV-1 latent reservoirs through therapeutic vaccination.
Pankrac J; Klein K; Mann JFS
AIDS Res Ther; 2017 Sep; 14(1):45. PubMed ID: 28893280
[TBL] [Abstract][Full Text] [Related]
13. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
[TBL] [Abstract][Full Text] [Related]
14. Policy rebuttal. HIV vaccine trial justified.
McNeil JG; Johnston MI; Birx DL; Tramont EC
Science; 2004 Feb; 303(5660):961. PubMed ID: 14963313
[No Abstract] [Full Text] [Related]
15. New strategies to combat HIV: augmenting antiviral immunity.
Smith KA; Boyle BA
AIDS Read; 2003 Aug; 13(8):365-9, 382. PubMed ID: 14524321
[No Abstract] [Full Text] [Related]
16. Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1.
Stratov I; Dale CJ; Chea S; McCluskey J; Kent SJ
J Virol; 2005 Jun; 79(12):7728-37. PubMed ID: 15919925
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
18. HIV vaccine efficacy trials: towards the future of HIV prevention.
Kim D; Elizaga M; Duerr A
Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
20. AIDS vaccine models: challenging challenge viruses.
Feinberg MB; Moore JP
Nat Med; 2002 Mar; 8(3):207-10. PubMed ID: 11875482
[No Abstract] [Full Text] [Related]
[Next] [New Search]
